PE16499A1 - Compuestos heterociclicos de guanidinilamino utiles como agonistas de alfa-2 adrenoreceptores - Google Patents

Compuestos heterociclicos de guanidinilamino utiles como agonistas de alfa-2 adrenoreceptores

Info

Publication number
PE16499A1
PE16499A1 PE1997001066A PE00106697A PE16499A1 PE 16499 A1 PE16499 A1 PE 16499A1 PE 1997001066 A PE1997001066 A PE 1997001066A PE 00106697 A PE00106697 A PE 00106697A PE 16499 A1 PE16499 A1 PE 16499A1
Authority
PE
Peru
Prior art keywords
alkyl
guanidinylamine
formula
alpha
hetero
Prior art date
Application number
PE1997001066A
Other languages
English (en)
Inventor
William Lee Seibel
Jeffrey Joseph Ares
Russell James Sheldon
Raymond Todd Henry
Thomas Lee Cupps
Sophie Eva Bogdan
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PE16499A1 publication Critical patent/PE16499A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIEREN A COMPUESTOS DE FORMULA (I), EN DONDE: R1 ES H, ALQUILO o NO EXISTE, CUANDO EL ENLACE (a) ES UN DOBLE ENLACE; "B" ES NR9, CR3=CR8, S, ENTRE OTROS; "D" ES CR2 o SI B ES CR3, ENTONCES "D" PUEDE SER NITROGENO, EN DONDE: R2 ES H, ALQUILO C1-C3, ENTRE OTROS; R9 ES H, ALQUILO C1-C3, ALQUENILO C1-C3, ALQUINILO C1-C3, CICLOALQUILO, CICLOALQUENILO; R3, R7 Y R8 SON H, ALQUILO C1-C3, ALQUENILO C1-C3, ALQUINILO C1-C3, ENTRE OTROS; R4, R5 Y R6 SON H, ALQUILO C1-C3, ALQUILTIO C1-C3, ALCOXI C1-C3, ENTRE OTROS, CON LA CONDICION DE QUE UNO DE R4, R5 Y R6 ES NH-NH-C(=NR10)NHR11 (GUANIDINILAMINO), EN DONDE: R10 Y R11 SON H, METILO o ETILO; SON COMPUESTOS PREFERIDOS: [(8-METILQUINOLINA-7-IL)AMINO]GUANIDINA Y [(4-METILBENCIMIDAZOL-5-IL)AMINO]GUANIDINA. TAMBIEN SE REFIERE A LA COMPOSICION QUE COMPRENDE UN COMPUESTO DE FORMULA (I) Y UNO O MAS PRINCIPIOS ACTIVOS SELECCIONADOS DE UN ANTIHISTAMINICO, UN ANTIINFLAMATORIO, ENTRE OTROS. LOS COMPUESTOS DE FORMULA (I) ACTUAN COMO AGONISTAS ALFA 2 ADRENORECEPTORES, SIENDO UTILES EN EL TRATAMIENTO DE LA CONGESTION NASAL, OTITIS MEDIA, SINUSITIS, ASMA, DOLOR, MIGRANA, ABUSO DE SUSTANCIAS Y ADICCION, TRASTORNO GASTROINTESTINAL, ULCERA, HIPERACIDEZ ESTOMACAL, HIPERTROFIA PROSTATICA BENIGNA, ENTRE OTROS
PE1997001066A 1996-11-25 1997-11-25 Compuestos heterociclicos de guanidinilamino utiles como agonistas de alfa-2 adrenoreceptores PE16499A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3183396P 1996-11-25 1996-11-25

Publications (1)

Publication Number Publication Date
PE16499A1 true PE16499A1 (es) 1999-03-12

Family

ID=21861650

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997001066A PE16499A1 (es) 1996-11-25 1997-11-25 Compuestos heterociclicos de guanidinilamino utiles como agonistas de alfa-2 adrenoreceptores

Country Status (23)

Country Link
EP (1) EP0944601B1 (es)
JP (1) JP2001504839A (es)
KR (1) KR20000069130A (es)
CN (1) CN1163486C (es)
AR (1) AR009144A1 (es)
AT (1) ATE232518T1 (es)
AU (1) AU729421B2 (es)
BR (1) BR9714362A (es)
CA (1) CA2272098C (es)
CZ (1) CZ183799A3 (es)
DE (1) DE69719068T2 (es)
DK (1) DK0944601T3 (es)
ES (1) ES2192703T3 (es)
HU (1) HUP0000479A3 (es)
ID (1) ID23038A (es)
IL (1) IL130023A0 (es)
NO (1) NO313286B1 (es)
NZ (1) NZ335859A (es)
PE (1) PE16499A1 (es)
SK (1) SK68599A3 (es)
TR (1) TR199901467T2 (es)
WO (1) WO1998023591A1 (es)
ZA (1) ZA9710575B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306877B1 (en) 1999-08-09 2001-10-23 The Procter & Gamble Co. Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
US6172095B1 (en) 1996-11-25 2001-01-09 The Procter & Gamble Company Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
NL1009376C1 (nl) * 1998-06-11 1998-07-06 Boardwalk Ag Datasysteem voor het verschaffen van relatiepatronen tussen personen.
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
WO2010074753A1 (en) 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576437A (en) * 1993-12-17 1996-11-19 The Procter & Gamble Company 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists

Also Published As

Publication number Publication date
CN1163486C (zh) 2004-08-25
NZ335859A (en) 2000-11-24
HUP0000479A3 (en) 2002-06-28
NO992503D0 (no) 1999-05-25
ID23038A (id) 2000-01-06
ATE232518T1 (de) 2003-02-15
CN1242001A (zh) 2000-01-19
JP2001504839A (ja) 2001-04-10
KR20000069130A (ko) 2000-11-25
BR9714362A (pt) 2000-03-21
DE69719068T2 (de) 2003-11-27
WO1998023591A1 (en) 1998-06-04
NO313286B1 (no) 2002-09-09
EP0944601B1 (en) 2003-02-12
NO992503L (no) 1999-07-23
EP0944601A1 (en) 1999-09-29
TR199901467T2 (xx) 1999-10-21
SK68599A3 (en) 2000-06-12
DE69719068D1 (de) 2003-03-20
CA2272098C (en) 2003-11-11
AU7402598A (en) 1998-06-22
ES2192703T3 (es) 2003-10-16
CA2272098A1 (en) 1998-06-04
ZA9710575B (en) 1998-06-10
IL130023A0 (en) 2000-02-29
DK0944601T3 (da) 2003-06-10
HUP0000479A2 (hu) 2000-09-28
CZ183799A3 (cs) 1999-09-15
AR009144A1 (es) 2000-03-08
AU729421B2 (en) 2001-02-01

Similar Documents

Publication Publication Date Title
PE16399A1 (es) Compuestos heterociclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptores
ES2172580T3 (es) 1,3-oxatiolanos sustituidos con propiedades antiviricas.
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
DE60015927D1 (en) Phenylharnstoff und phenylthioharnstoffderivate
PE20081557A1 (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
TR200103335T2 (tr) Proteaz inhibitörleri olarak amin türevleri
PE16299A1 (es) Compuestos de 2-imidazolinilaminoindol utiles como agonistas de alfa-2 adrenoreceptores
PE20040526A1 (es) Amidas de 4-alquenil piperidina de indol, azaindol y relacionadas con heterociclicos
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
TR200102800T2 (tr) Yeni bileşikler.
PE20050460A1 (es) COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO)
PE20040772A1 (es) Composicion y actividad antiviral de derivados de piperazina azaindoloxoaceticos
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
CO5271666A1 (es) Derivados de pirimidina
PE83999A1 (es) Azetidinas
ATE205484T1 (de) Aminotetrazol-derivate verwendbar als stickstoff- oxid-synthase inhibitoren
AR017019A1 (es) Compuestos derivados del 2-(4-aril o heteroarilpiperazin-1-ilmetil)-1h-indol, composiciones y su uso en la manufactura de medicamentos
SE0102055D0 (sv) New Compounds
DE69626981T2 (de) N-(2-oxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3-yl)-3-amide
UY25211A1 (es) Inhibidores de isoquinolinilguanidina uroquinasa
PE16599A1 (es) Compuestos de (2-imidazolinilamino) benzoxazol utiles como agonistas de alfa-2 adrenoreceptores
PE16499A1 (es) Compuestos heterociclicos de guanidinilamino utiles como agonistas de alfa-2 adrenoreceptores
HUP0203787A2 (hu) Hidroxi-acetil-piperazinnal szubsztituált oxazolidinon-benzoesav-észterek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ES2180932T3 (es) Derivados de camptotecina y su uso como agentes antitumorales.
PE20010485A1 (es) Derivados de bencimidazol sustituidos con aminocarbonilo, procedimiento para su preparacion y su utilizacion como medicamentos

Legal Events

Date Code Title Description
FX Voluntary withdrawal